Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurotech International Ltd. ( (AU:NTI) ) just unveiled an update.
Neurotech International Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO Dr. Anthony Filippis will present the company’s refined strategy aimed at accelerating revenue generation and commercialization opportunities. The strategy includes advancing regulatory approvals in Australia and the USA, developing strategic partnerships, and leveraging clinical data to drive early revenue opportunities. This approach is expected to unlock Neurotech’s potential and create value for shareholders and patients.
More about Neurotech International Ltd.
Neurotech International Limited is a clinical-stage biopharmaceutical development company primarily focused on pediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164, which has shown clinically meaningful and statistically significant benefits in trials for Autism Spectrum Disorder (ASD) and other pediatric neuropsychiatric conditions. Neurotech is advancing its research with human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.
YTD Price Performance: -36.67%
Average Trading Volume: 702,239
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$39.6M
For an in-depth examination of NTI stock, go to TipRanks’ Stock Analysis page.